Equities

Imunon Inc

Imunon Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.33
  • Today's Change0.02 / 1.53%
  • Shares traded54.61k
  • 1 Year change+5.56%
  • Beta2.0688
Data delayed at least 15 minutes, as of May 03 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases. The Company is developing non-viral Deoxyribonucleic acid (DNA) technology across four modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit a strong immunological response. The third modality, FixPlas, concerns the application of Imunon’s DNA technology to produce universal cancer vaccines, also called tumor associated antigen cancer vaccines. The fourth modality, IndiPlas, is in the discovery phase and is focused on the development of personalized cancer vaccines, or neoepitope cancer vaccines. Its lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer.

  • Revenue in USD (TTM)0.00
  • Net income in USD-19.51m
  • Incorporated2000
  • Employees33.00
  • Location
    Imunon Inc997 Lenox Dr Ste 100LAWRENCEVILLE 08648United StatesUSA
  • Phone+1 (609) 896-9100
  • Fax+1 (609) 896-2200
  • Websitehttps://imunon.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
ABVC Biopharma Inc152.43k-10.52m11.41m16.00--1.02--74.82-2.52-2.520.03521.060.0127--0.35149,526.88-90.65-103.38-171.60-231.54-98.1576.25-7,157.57-2,019.89---3.280.153---84.2885.3935.97------
Pioneer Green Farms Inc9.29k-403.37k11.94m6.00------1,285.15-0.0172-0.01720.0004-0.0260.01540.3035--1,548.33-66.94------41.44---4,341.98--0.0106-30.89--------35.41------
ELEVAI Labs Inc1.71m-4.30m12.15m18.00--3.17--7.09-0.2482-0.24820.09880.2208------95,143.89--------66.25---251.17--3.41-41.160.00--123.50---138.94------
Viaderma Inc17.80m2.31m12.28m75.000.00060.000042.270.6916.8416.84129.62255.590.412624.691.21237,331.305.36--6.53--28.90--12.99--2.075.660.1718---29.15---40.70------
Energy Finders Inc4.06m-2.92m12.30m46.00------3.03-0.272-0.2721.523.04------88,304.35--------27.45---71.79--0.6706-12.570.564--------------
Imunon Inc0.00-19.51m12.50m33.00--0.9338-----2.17-2.170.001.420.00----0.00-59.23-50.18-80.53-60.27-------5,725.88----0.00---100.00--45.64--26.69--
Monopar Therapeutics Inc0.00-8.40m12.69m10.00--1.94-----0.612-0.6120.000.37490.00----0.00-81.69-54.07-107.13-60.60------------0.00------20.10------
Check Cap Ltd0.00-17.62m12.87m85.00--0.4698-----3.01-3.010.004.680.00----0.00-44.86-58.80-48.21-66.41------------0.00-------11.08--16.04--
Coeptis Therapeutics Holdings Inc0.00-21.27m12.99m5.00--2.95-----0.8922-0.89220.000.12210.00----0.00-266.05-36.90-392.90-37.81------------0.2068------43.40------
NanoViricides Inc0.00-9.36m13.31m7.00--1.15-----0.8004-0.80040.000.98280.00----0.00-55.47-43.54-57.90-46.29------------0.00-------5.94---8.90--
Actavia Life Sciences Inc0.00-4.44m13.35m1.00---------0.0074-0.00740.00-0.00270.00----0.00-10,235.89-158.17---------------21.20---------547.04------
Lotus Pharmaceuticals Inc70.79m1.72m13.47m233.000.09040.00143.490.19030.05530.05532.563.580.632137.2717.85303,836.901.5522.841.7126.4035.1041.622.4519.930.442830.800.05160.0028.7131.70-12.2251.1170.48--
Kiora Pharmaceuticals Inc0.00-13.04m13.48m12.00--0.6474-----2.98-2.980.000.79290.00----0.00-77.27-70.52-91.06-81.86-------2,040.61----0.00------3.97------
Dominari Holdings Inc2.04m-22.88m13.65m26.00--0.2579--6.69-4.44-4.440.38998.920.0305--0.382978,423.08-34.20-26.82-35.10-27.45-----1,122.22-3,353.52----0.00----135.7512.72--63.99--
Data as of May 03 2024. Currency figures normalised to Imunon Inc's reporting currency: US Dollar USD

Institutional shareholders

4.27%Per cent of shares held by top holders
HolderShares% Held
Renaissance Technologies LLCas of 31 Dec 202392.11k0.98%
Geode Capital Management LLCas of 31 Dec 202366.60k0.71%
BlackRock Fund Advisorsas of 31 Dec 202358.58k0.62%
The Vanguard Group, Inc.as of 31 Dec 202348.81k0.52%
Citadel Securities LLCas of 31 Dec 202329.63k0.32%
HRT Financial LLCas of 31 Dec 202328.57k0.30%
Virtu Americas LLCas of 31 Dec 202325.86k0.28%
G1 Execution Services LLCas of 31 Dec 202322.86k0.24%
SSgA Funds Management, Inc.as of 31 Dec 202314.30k0.15%
Two Sigma Securities LLCas of 31 Dec 202313.84k0.15%
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.